← Back to Search
Pan-FGFR Inhibition Leads To Blockade Of FGF23 Signaling, Soft Tissue Mineralization, And Cardiovascular Dysfunction.
G. Yanochko, A. Vitsky, J. R. Heyen, B. Hirakawa, J. Lam, J. May, T. Nichols, F. Sace, D. Trajkovic, E. Blasi
Published 2013 · Biology, Medicine
Save to my Library
Download PDFAnalyze on Scholarcy
The fibroblast growth factor receptors (FGFR) play a major role in angiogenesis and are desirable targets for the development of therapeutics. Groups of Wistar Han rats were dosed orally once daily for 4 days with a small molecule pan-FGFR inhibitor (5mg/kg) or once daily for 6 days with a small molecule MEK inhibitor (3mg/kg). Serum phosphorous and FGF23 levels increased in all rats during the course of the study. Histologically, rats dosed with either drug exhibited multifocal, multiorgan soft tissue mineralization. Expression levels of the sodium phosphate transporter Npt2a and the vitamin D-metabolizing enzymes Cyp24a1 and Cyp27b1 were modulated in kidneys of animals dosed with the pan-FGFR inhibitor. Both inhibitors decreased ERK phosphorylation in the kidneys and inhibited FGF23-induced ERK phosphorylation in vitro in a dose-dependent manner. A separate cardiovascular outcome study was performed to monitor hemodynamics and cardiac structure and function of telemetered rats dosed with either the pan-FGFR inhibitor or MEK inhibitor for 3 days. Both compounds increased blood pressure (~+ 17 mmHg), decreased heart rate (~-75 bpm), and modulated echocardiography parameters. Our data suggest that inhibition of FGFR signaling following administration of either pan-FGFR inhibitor or MEK inhibitor interferes with the FGF23 pathway, predisposing animals to hyperphosphatemia and a tumoral calcinosis-like syndrome in rodents.
This paper references
Toxicity of the fibroblast growth factor inhibitor, PD 176067, in juvenile and adult dogs
K. Datta (2003)
Mutation of the mouse klotho gene leads to a syndrome resembling ageing
M. Kuroo (1997)
FGF23 acts directly on renal proximal tubules to induce phosphaturia through activation of the ERK1/2–SGK1 signaling pathway
O. Andrukhova (2012)
FGF23 is a novel regulator of intracellular calcium and cardiac contractility in addition to cardiac hypertrophy.
C. Touchberry (2013)
Phase I/II and Pharmacodynamic Study of Dovitinib (TKI258), an Inhibitor of Fibroblast Growth Factor Receptors and VEGF Receptors, in Patients with Advanced Melanoma
K. Kim (2011)
Administration of a MEK inhibitor results in tissue mineralization in the rat due to dysregulation of phosphorus and calcium homeostasis
A. Brown (2005)
Targeted deletion of Klotho in kidney distal tubule disrupts mineral metabolism.
H. Olauson (2012)
Homozygous ablation of fibroblast growth factor-23 results in hyperphosphatemia and impaired skeletogenesis, and reverses hypophosphatemia in Phex-deficient mice.
D. Sitara (2004)
Reversal of mineral ion homeostasis and soft-tissue calcification of klotho knockout mice by deletion of vitamin D 1alpha-hydroxylase.
Mutsuko Ohnishi (2009)
FGF23 decreases renal NaPi-2a and NaPi-2c expression and induces hypophosphatemia in vivo predominantly via FGF receptor 1.
J. Gattineni (2009)
Fibroblast growth factor (FGF) receptor 1-IIIb is a naturally occurring functional receptor for FGFs
H. D. Beer (2000)
Targeted ablation of Fgf23 demonstrates an essential physiological role of FGF23 in phosphate and vitamin D metabolism.
T. Shimada (2004)
Fibroblast growth factor receptor (FGFR) 3. Alternative splicing in immunoglobulin-like domain III creates a receptor highly specific for acidic FGF/FGF-1.
A. Chellaiah (1994)
Regulation of phosphate transport.
K. Hruska (1997)
Fibroblast growth factor signalling: from development to cancer
N. Turner (2010)
Structural, functional, and molecular characterization of the SHHF model of heart failure.
J. Heyen (2002)
FGF23 induces left ventricular hypertrophy.
C. Faul (2011)
Fibroblast growth factor receptors and their ligands in the adult rat kidney.
B. Cancilla (2001)
Regulation of phosphate homeostasis by PTH, vitamin D, and FGF23.
C. Bergwitz (2010)
Adverse effects of hyperphosphatemia on myocardial hypertrophy, renal function, and bone in rats with renal failure.
K. Neves (2004)
A phase I study to determine the safety, pharmacokinetics and pharmacodynamics of a dual VEGFR and FGFR inhibitor, brivanib, in patients with advanced or metastatic solid tumors.
D. Jonker (2011)
Nitric oxide and adverse events of vascular endothelial growth factor inhibitors
J. Thachil (2011)
Fundamentals of Veterinary Clinical Pathology
S. Stockham (2002)
Klotho converts canonical FGF receptor into a specific receptor for FGF23
I. Urakawa (2006)
The FGF family: biology, pathophysiology and therapy
A. Beenken (2009)
A novel form of FGF receptor‐3 using an alternative exon in the immunoglobulin domain III
A. Avivi (1993)
Regulation of phosphate transport by fibroblast growth factor 23 (FGF23): implications for disorders of phosphate metabolism
J. Gattineni (2009)
Cartilage Dysplasia and Tissue Mineralization in the Rat Following Administration of a FGF Receptor Tyrosine Kinase Inhibitor
Alan P. Brown (2005)
Chronic inhibition of ERK1/2 signaling improves disordered bone and mineral metabolism in hypophosphatemic (Hyp) mice.
M. Y. Zhang (2012)
Fibroblast Growth Factor (FGF) Receptor 1-IIIb Is a Naturally Occurring Functional Receptor for FGFs That Is Preferentially Expressed in the Skin and the Brain*
H. D. Beer (2000)
Sunitinib, a receptor tyrosine kinase inhibitor, increases blood pressure in rats without associated changes in cardiac structure and function.
E. Blasi (2012)
Development of Serum Calcium and Phosphorus as Clinical Biomarkers for Drug‐Induced Systemic Mineralization: Case Study with a MEK Inhibitor
A. Brown (2010)
Initial FGF23-mediated signaling occurs in the distal convoluted tubule.
E. Farrow (2009)
Phosphate dysregulation following pan-FGFR inhibition in rodents
A. Vitsky (2011)
Phosphorous dysregulation induced by MEK small molecule inhibitors in the rat involves blockade of FGF-23 signaling in the kidney.
Dolores Diaz (2012)
G. Rusak (1955)
Genetic ablation of vitamin D activation pathway reverses biochemical and skeletal anomalies in Fgf-23-null animals.
D. Sitara (2006)
Incisor Degeneration in Rats Induced by Vascular Endothelial Growth Factor/Fibroblast Growth Factor Receptor Tyrosine Kinase Inhibition
A. M. Fletcher (2010)
Compound deletion of Fgfr3 and Fgfr4 partially rescues the Hyp mouse phenotype.
H. Li (2011)
FGFR3 and FGFR4 do not mediate renal effects of FGF23.
S. Liu (2008)
Role of Anti-angiogenesis Agents in Treating NSCLC: Focus on Bevacizumab and VEGFR Tyrosine Kinase Inhibitors
Elwyn C. Cabebe (2007)
Regulation of Fibroblast Growth Factor-23 Signaling by Klotho*
H. Kurosu (2006)
Regulation of phosphate transport in proximal tubules
J. Biber (2008)
Phosphate regulation of vascular smooth muscle cell calcification.
S. Jono (2000)
Fibroblast growth factor 23 regulates renal 1,25‐dihydroxyvitamin D and phosphate metabolism via the MAP kinase signaling pathway in Hyp mice
Daniel Ranch (2011)
Molecular Pathways: Fibroblast Growth Factor Signaling: A New Therapeutic Opportunity in Cancer
A. N. Brooks (2012)
This paper is referenced by
Investigational drugs targeting fibroblast growth factor receptor in the treatment of non-small cell lung cancer
E. Rijavec (2017)
Renal FGFR 1 signaling and blood pressure regulation 1
M. Publishers (2018)
Mechanisms of soft-tissue mineralization induced by the inhibition of the MEK/ERK pathway or the inhibition of fibroblast growth factor receptors
João A Graça (2016)
Activation of Cardiac Fibroblast Growth Factor Receptor 4 Causes Left Ventricular Hypertrophy.
A. Grabner (2015)
FGF23 in Cardiovascular Disease: Innocent Bystander or Active Mediator?
R. Stoehr (2018)
Facts and New Hopes on Selective FGFR Inhibitors in Solid Tumors
F. Facchinetti (2019)
The use of fibroblast growth factor 23 testing in patients with kidney disease.
E. Smith (2014)
RedesigningaMonospeci fi cAnti-FGFR 3 Antibody to Add Selectivity for FGFR 2 and Expand Antitumor Activity
Yiyuan Yin (2015)
FGF23/FGFR4-mediated left ventricular hypertrophy is reversible
A. Grabner (2017)
Metastatic Calcinosis Cutis Associated With a Selective FGFR Inhibitor.
D. Carr (2019)
A Pan-GTPase Inhibitor as a Molecular Probe
L. Hong (2015)
Development of Serum Calcium and Phosphorus as Safety Biomarkers for Drug‐Induced Systemic Mineralization: Case Study with the MEK Inhibitor PD 0325901 1
Alan P. Brown (2020)
Off-target effects and adverse outcomes of fibroblast growth factor 23 in chronic kidney disease
G. D. Marco (2018)
Repurposing an anti‐cancer agent for the treatment of hypertrophic heart disease
Matthew S Dukinfield (2019)
FGF23 from bench to bedside.
C. Kovesdy (2016)
Fibroblast growth factor 23: are we ready to use it in clinical practice?
Annet Bouma-de Krijger (2020)
Corrigendum: FGF23 in Cardiovascular Disease: Innocent Bystander or Active Mediator?
R. Stoehr (2018)
Treatment of established left ventricular hypertrophy with fibroblast growth factor receptor blockade in an animal model of CKD.
G. D. di Marco (2014)
Targeting the FGFR signaling pathway in cholangiocarcinoma: promise or delusion?
J. Wang (2020)
A Phase 1 Study of LY2874455, an Oral Selective pan-FGFR Inhibitor, in Patients with Advanced Cancer
M. Michael (2017)
A phase II trial of single oral FGF inhibitor, AZD4547, as second or third line therapy in malignant pleural mesothelioma.
Wei-Sen Lam (2019)
Redesigning a Monospecific Anti-FGFR3 Antibody to Add Selectivity for FGFR2 and Expand Antitumor Activity
Y. Yin (2015)
Genetic renal disease classification by hormonal axes
Bar Rotem-Grunbaum (2019)
Metastatic Calcinosis Cutis Secondary to Selective Fibroblast Growth Factor Receptor Inhibitor: Rapid and Complete Regression after Blood Phosphate Normalization and Drug Withdrawal.
Daniel Lopez-Castillo (2020)
Clinical complexity of utilizing FGFR inhibitors in cancer therapeutics
S. Chandana (2020)
Sustained Brown Fat Stimulation and Insulin Sensitization by a Humanized Bispecific Antibody Agonist for Fibroblast Growth Factor Receptor 1/βKlotho Complex
G. Kolumam (2015)
Futibatinib Is a Novel Irreversible FGFR 1–4 Inhibitor That Shows Selective Antitumor Activity against FGFR-Deregulated Tumors
Hiroshi Sootome (2020)
Oral administration of oleuropein attenuates cisplatin-induced acute renal injury in mice through inhibition of ERK signaling.
Iva Potočnjak (2016)
Fibroblast Growth Factor 23 and Adverse Clinical Outcomes in Type 2 Diabetes: a Bitter-Sweet Symphony
Stanley M H Yeung (2020)
Effect of anti-fibroblast growth factor receptor 1 antibodies on phosphorus metabolism in laying hens and their progeny chicks.
Z. Ren (2019)
Oncogenic Characterization and Pharmacologic Sensitivity of Activating Fibroblast Growth Factor Receptor (FGFR) Genetic Alterations to the Selective FGFR Inhibitor Erdafitinib
Jayaprakash D Karkera (2017)
A novel monovalent FGFR1 antagonist: Preclinical safety profiles in rodents and non-human primates.
P. Yu (2020)See more